In mouse gastric dysplastic Meta4 organoids, STAT3-IN-1 (1 μM, 3 days) arrested growth without inducing cell death. A separate comparison using STAT3-IN-1 (500 nM) with trametinib (1 μM) for 3 days produced cell death. These findings distinguish single-agent growth suppression from the combination response in this model. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Single-agent response in mouse gastric dysplastic organoids
Cell-based study · Mouse gastric dysplastic Meta4 organoids derived from Mist1-Kras mice [1]
STAT3-IN-1 arrested organoid growth without inducing cell death in the reported three-day comparison. DMSO, pyrvinium, Stattic and cryptotanshinone were parallel controls/comparators.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 3 days
- Method
- Organoid exposure followed by imaging and diameter assessment
- Vehicle
- DMSO vehicle control
- Reported limits
- Final DMSO fraction and organoid-level sample count are not specified in the read Figure 3F–G caption. The caption states n = 3 biological replicates; shared methods state experiments were repeated three times.
Methods and source locations
Compound reported in the paper: STAT3-IN-1; Compound label in the paper: STAT3-IN-1
Results apply to the reported supplier-named reagent in these organoids; chemical purity, stereochemical composition and equivalence to an Adooq lot were not established.
Figure 3F–G; associated Results; Methods: Organoid culture and Quantification and Statistical Analysis
Organoid diameter and morphology before and after treatment: Phase-contrast images and ImageJ diameter measurements; Figure 3F–G. No exact diameters inferred from violin plots. — Figure 3F–G and associated Results paragraph beginning “We additionally treated the Meta3 and Meta4 organoids”
STAT3-IN-1 plus trametinib in mouse gastric dysplastic organoids
Cell-based study · Mouse gastric dysplastic Meta4 organoids derived from Mist1-Kras mice [1]
Combined STAT3-IN-1 and trametinib produced cell death and reduced organoid size in the reported comparison with DMSO and individual treatments. This is a combination result.
Literature-Reported Treatment Conditions
- Treatment concentration
- STAT3-IN-1: 500 nM; trametinib: 1 μM
- Exposure duration
- 3 days
- Method
- Organoid exposure to individual agents or their combination
- Vehicle
- DMSO vehicle control
- Co-treatment
- Trametinib (Tra), 1 μM, co-treatment
- Reported limits
- Final DMSO fraction and organoid-level sample count are not specified in the read Figure 3H–I caption. The caption states n = 3 biological replicates; shared methods state experiments were repeated three times.
Methods and source locations
Compound reported in the paper: STAT3-IN-1; Compound label in the paper: STAT3-IN-1; Tra + STAT3-IN-1
Results apply to the reported supplier-named reagent in these organoids; chemical purity, stereochemical composition and equivalence to an Adooq lot were not established.
Figure 3H–I; associated Results; Methods: Organoid culture and Quantification and Statistical Analysis
Organoid diameter and morphology before and after single or combined treatment: Phase-contrast imaging and ImageJ diameter assessment in Figure 3H–I; no numerical effect size or synergy score inferred. — Figure 3H–I and associated Results paragraph contrasting single inhibitors with co-treatment